J Zafra Martin, J L Onieva, A Roman, M Garrido, J Oliver, B Martinez-Galvez, J Dubbelman, A Mesas, R Villatoro, I Ramos, A Rueda-Dominguez, E Perez-Ruiz, J C Benitez, J A Medina, E Alba, R Chicas Sett, I Barragan
PURPOSE/OBJECTIVE(S): Up to 80% of metastatic patients face resistance to immune checkpoint inhibitors (ICI). Combined SABR and ICI (I-SABR) can unleash antitumor immune cascades to overcome resistance and improve response with minimal toxicity. This synergy is particularly interesting in the oligoprogressive setting to extend the clinical benefit (CB) of ICI. However, there are no current biomarkers for patient selection. We hypothesize that differential expression of exosomal RNA in liquid biopsy may predict response to I-SABR...
October 1, 2023: International Journal of Radiation Oncology, Biology, Physics